About Nova Sud Pharmaceuticals Private Limited
Data last updated:
Nova Sud Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Medplus Health Services Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 12 October 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2007PTC055895. Its GSTIN is 36AAFCP1772L1Z3 (Telangana).
The company has an authorised share capital of ₹6.86 Cr and a paid-up capital of ₹6.86 Cr. It was formerly known as Panindia Pharma Distributors Private Limited. It is led by directors including Phani Srinivas Ramella and Bhaskar Reddy Cherukupalli.
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.3 – 4 – 97/Q/Nr/ Within St. John Seminary Compound Ramanthpur, Hyderabad, Telangana, India – 500013.
As per the financials filed for FY 2025, the company reported a revenue of ₹12.7 Lakh, a decline of 95% compared to the previous year. For the same year it recorded a net loss of ₹5.8 Lakh (net margin -45.7%) and EBITDA of -₹5.2 Lakh (EBITDA margin -40.9%). Revenue has declined at a compounded annual rate (CAGR) of 59% over three years.
Its group structure includes 5 subsidiaries.
The company has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medplusindia.com.
Company details
CIN history
Nova Sud Pharmaceuticals has one previous CIN (Corporate Identification Number): U24232AP2007PTC055895. The current CIN is U24232TG2007PTC055895, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC055895 | Current |
| U24232AP2007PTC055895 | Previous |
Contact details
Nova Sud Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is medplusindia.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Apps
- Registered AddressNo.3 – 4 – 97/Q/Nr/ Within St. John Seminary Compound Ramanthpur, Hyderabad, Telangana, India – 500013
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Nova Sud Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Nova Sud Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Nova Sud Pharmaceuticals Private Limited, buy the company report.
Financials of Nova Sud Pharmaceuticals Private Limited
FY 2025 filings availableNova Sud Pharmaceuticals Private Limited reported revenue of ₹12.7 Lakh (down 95% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 59% over three years, including a 95% fall in the latest year. EBITDA fell 117% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹5.2 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹5.8 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -40.9% | ||||
| Net Profit Margin | -45.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nova Sud Pharmaceuticals Private Limited, buy the company report.
Board of directors of Nova Sud Pharmaceuticals Private Limited
Nova Sud Pharmaceuticals has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Phani Srinivas Ramella Also directs: Sai Sridhar Pharma Private Limited, Deccan Medisales Private Limited, Medplus Insurance Brokers Private Limited and 3 more | Director | 31 Jul 2014 | 12 Years 2 Months | Current |
| Bhaskar Reddy Cherukupalli Also directs: Agilepro (India) Ventures LLP, Medplus Health Services Limited, Wynclark Pharmaceuticals Private Limited and 5 more | Director | 26 May 2024 | 2 Years 4 Months | Current |
| Satya Murali Krishna Kammila Also directs: Wynclark Pharmaceuticals Private Limited, Clearancekart Private Limited, Kalyani Meditimes Private Limited and 5 more | Director | 29 Sep 2021 | 5 Years 0 Months | Current |
Auditor
Nova Sud Pharmaceuticals Private Limited is audited by Gphk & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Gphk & Associates | FY 2023 | 008053S |
Shareholding
The shareholding of Nova Sud Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Nova Sud Pharmaceuticals Private Limited, buy the company report.
Deals & funding
Nova Sud Pharmaceuticals Private Limited has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021.
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2021 | Funding round | ₹50 Lakh | Investors: Medplus Health Services Limited |
| Oct 2017 | Funding round | ₹2 Cr | Investors: Medplus Health Services Limited |
| Mar 2016 | Funding round | ₹1.7 Cr | Investors: Medplus Health Services Limited |
| Jan 2015 | Funding round | ₹1 Cr | Investors: Medplus Health Services Limited |
| Mar 2014 | Funding round | ₹15 Lakh | Investors: Medplus Health Services Limited |
To see the full deal history of Nova Sud Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Nova Sud Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nova Sud Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Nova Sud Pharmaceuticals has 5 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Sai Sridhar Pharma Private Limited | U24232TG2007PTC055902 | |
| Deccan Medisales Private Limited | U51397KA2011PTC059204 | |
| Venkata Krishna Enterprises Private Limited | U51909TG2010PTC071012 | |
| Shri Banashankari Pharma Private Limited | U74900KA2014PTC074302 | |
| Sidson Pharma Distributors Private Limited | U74900TG2014PTC092145 |
To see the full group structure of Nova Sud Pharmaceuticals Private Limited, buy the company report.
GST
Nova Sud Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCP1772L1Z3 | Telangana | Active | 05 Dec 2019 |
To see the full GST registrations and return filing status of Nova Sud Pharmaceuticals Private Limited, buy the company report.
Recent activity
Nova Sud Pharmaceuticals Private Limited has 8 board changes on record since 2014: 3 appointments and 5 cessations. The latest: Bhaskar Reddy Cherukupalli was appointed as Director on 26 May 2024.
Frequently asked questions
Nova Sud Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 12 October 2007 (19+ years old) and is registered under CIN U24232TG2007PTC055895.
Nova Sud Pharmaceuticals has 3 current directors:
- Phani Srinivas Ramella - Director
- Bhaskar Reddy Cherukupalli - Director
- Satya Murali Krishna Kammila - Director
The latest financial statements of Nova Sud Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 05 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Nova Sud Pharmaceuticals is 36AAFCP1772L1Z3, registered in Telangana.
The CIN (Corporate Identification Number) of Nova Sud Pharmaceuticals is U24232TG2007PTC055895. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nova Sud Pharmaceuticals was incorporated on 12 October 2007, making it 19+ years old. It is registered with the Registrar of Companies, Hyderabad.
Nova Sud Pharmaceuticals has 8 deals on record (5 funding rounds, 2 acquisitions, 1 secondary share transfer), with disclosed funding of ₹5.35 Cr; the latest was in March 2021.
Bhaskar Reddy Cherukupalli was appointed as Director on 26 May 2024. Prasad Reddy Battinapatla ceased to be Director on 25 Apr 2024. Ravi Venkat Reddy ceased to be Director on 27 Sep 2023. Nova Sud Pharmaceuticals has 8 board changes on record in total.
Nova Sud Pharmaceuticals can be reached through the website medplusindia.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of Nova Sud Pharmaceuticals is at No.3 – 4 – 97QNr Within St. John Seminary Compound Ramanthpur, Hyderabad, Telangana, India – 500013.